Back to discover

Protein / target

Receptor tyrosine-protein kinase erbB-4

Encoded byERBB4Q15303Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
6
Approved medicines
Open Targets target-level
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Transmembrane receptor protein tyrosine kinase

Primary biology

EGFR/ERBB growth-factor signalling

Strongest disease association

Polycystic Ovary Syndrome

Via encoding gene ERBB4 · Genetic evidence · score 0.87

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis.

View complete UniProt function annotation

Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis

Subcellular location

Cell membraneNucleusMitochondrion
Domains and Gene Ontology detail (63)

Domains & features

Protein kinase

Gene Ontology

  • Cbasal plasma membrane
  • Cbasolateral plasma membrane
  • Ccytosol
  • Cextracellular region
  • CGABA-ergic synapse
  • Cglutamatergic synapse
  • Cmitochondrial matrix
  • Cmitochondrion
  • Cneuromuscular junction
  • Cnucleoplasm
  • Cnucleus
  • Cplasma membrane

1308 aa · 147 kDa · 4 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Receptor tyrosine kinase signallingUniProt · GO · ReactomeCell migrationUniProt · GO · ReactomeCell proliferation & survivalGO · ReactomeSynaptic signallingGOGrowth-factor signallingGOOncogenic signallingReactome
View supporting evidence

Receptor tyrosine kinase signalling

  • ·Tyrosine-protein kinase that plays an essential role as cell surface receptor for neureg…
  • ·transmembrane receptor protein tyrosine kinase activity
  • ·cell surface receptor protein tyrosine kinase signaling pathway
  • ·ERBB2-ERBB4 signaling pathway

Cell migration

  • ·Tyrosine-protein kinase that plays an essential role as cell surface receptor for neureg…
  • ·cell migration
  • ·neural crest cell migration
  • ·regulation of cell migration

Cell proliferation & survival

  • ·negative regulation of cell population proliferation
  • ·positive regulation of cell population proliferation
  • ·PIP3 activates AKT signaling
  • ·PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling

Synaptic signalling

  • ·GABA-ergic synapse
  • ·glutamatergic synapse
  • ·postsynaptic density membrane
  • ·postsynaptic membrane

Growth-factor signalling

  • ·epidermal growth factor receptor activity
  • ·epidermal growth factor receptor binding
  • ·epidermal growth factor receptor signaling pathway

Oncogenic signalling

  • ·Constitutive Signaling by Aberrant PI3K in Cancer
View underlying pathways (20)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

ERBB3SHC1BTCNRG3NRG2GRB2EGFEREGHBEGFNRG1ERBB4

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

neratinib
Narrow target profileApprovedInhibitor

Receptor protein-tyrosine kinase erbB-4 inhibitor

Direct interaction with this protein · 1 of 3 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene ERBB4

Gene-level evidence surfaced through the gene ERBB4that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Polycystic Ovary Syndrome
0.87Well supported

Genetic evidence dominant · Open Targets 0.54

Neoplasms
0.87Well supported

Clinical evidence dominant · Open Targets 0.61

Carcinoma, Non-Small-Cell Lung
0.84Well supported

Clinical evidence dominant · Open Targets 0.68

Atrial Fibrillation
0.84Well supported

Genetic evidence dominant · Open Targets 0.51

Genetic Diseases, Inborn
0.83Well supported

Genetic evidence dominant · Open Targets 0.51

View evidence synthesis (5)
Polycystic Ovary SyndromeWell supported
0.87
agreement 0.731.00
Genetic94%Literature7%

Open Targets aggregate 0.54 · 2 independent evidence families

NeoplasmsWell supported
0.87
agreement 0.770.98
Clinical44%Pathway26%Somatic mutation20%Literature10%

Open Targets aggregate 0.61 · 4 independent evidence families

Carcinoma, Non-Small-Cell LungWell supported
0.84
agreement 0.720.96
Clinical63%Somatic mutation26%Literature11%

Open Targets aggregate 0.68 · 3 independent evidence families

Atrial FibrillationWell supported
0.84
agreement 0.700.97
Genetic95%Literature5%

Open Targets aggregate 0.51 · 2 independent evidence families

Genetic Diseases, InbornWell supported
0.83
agreement 0.690.97
Genetic99%Literature1%

Open Targets aggregate 0.51 · 2 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Carcinoma, Non-Small-Cell Lung0.68
Amyotrophic Lateral Sclerosis0.66
Neoplasms0.61
Breast Neoplasms0.58
Medullary thyroid gland carcinoma0.55
Polycystic Ovary Syndrome0.54
Atrial Fibrillation0.51
Genetic Diseases, Inborn0.51

Drug development

15 compounds recorded · 6 approved · 9 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph: these count different sets and are not a subset relation.

View all recorded compounds (10)
KBP5209Phase 1
AFATINIB DIMALEATEApproval
VANDETANIBApproval
NERATINIB MALEATEApproval
POZIOTINIBPhase 3
CANERTINIB DIHYDROCHLORIDEPhase 2
JNJ-26483327Phase 1
CANERTINIBPhase 2
DACOMITINIB ANHYDROUSPhase 2
DACOMITINIBApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

Other modalitiesSupported

Phase 1 Clinical support this modality.

View underlying tractability evidence (13)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule BinderOC · Phase 1 Clinical

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

RECRUITING · via neratinib · NCT05919108

ACTIVE_NOT_RECRUITING · via neratinib · NCT02932280

ClinicalTrials.gov via the drug-target graph.

What's happening now

3

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Trial status changed2026-07-22

    Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

    Status changed to Terminated · ClinicalTrials.gov · via neratinib

  2. New publication2020-09-10
    Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.

    The Lancet. Oncology · 2020 · 274 citations · Europe PMC · via neratinib

  3. Regulatory approval2018-08-31

    Approval: Nerlynx (EMA)

    ema · regulatory · ema · via neratinib

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.

Related family literature

51

Papers about “ErbB Receptors” — a broader family this protein belongs to. Shown as context; not counted as papers specifically about this protein.

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy.

Raskova Kafkova L · Frontiers in immunology · 2024

via ErbB Receptors

Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i>-Mutated Advanced NSCLC.

Cho BC · The New England journal of medicine · 2024

via ErbB Receptors

Europe PMC literature, reached through curated HGNC family membership. Membership is a taxonomic relationship — it does not imply this protein participates in every mechanism these papers discuss.